Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AC Immune SA

www.acimmune.com

Latest From AC Immune SA

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Clinical Trials Neurology

AC Immune CEO Outlines ‘Roadmap’ For Fighting Alzheimer’s

AC Immune’s CEO tells Scrip that treating earlier, targeting Tau, and focusing on more homogeneous populations will be needed to successfully fight Alzheimer’s Disease.

Companies Strategy

Parkinson’s Disease: Novel Science And Collaborations Fuel Progress

Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.

BioPharmaceutical Neurology

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
  • Therapeutic Areas
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • AC Immune SA
  • Senior Management
  • Andrea Pfeifer, PhD, CEO
    Joerg Hornstein, CFO
    Andreas Muhs, PhD, CSO
  • Contact Info
  • AC Immune SA
    Phone: (41) 21 693 91 21
    EPFL Innovation Park
    Bldg. B
    Lausanne, 1015
    Switzerland
UsernamePublicRestriction

Register